Table 1 Baseline clinical characteristics
Characteristics | All (n = 9709) | Lp(a) (mg/dL) | p-value | |||
|---|---|---|---|---|---|---|
Quartile1 (n = 2428) | Quartile2 (n = 2426) | Quartile3 (n = 2428) | Quartile4 (n = 2427) | |||
(< 8.9) | (8.9, 18.1) | (18.1, 35.8) | (> 35.8) | |||
Demographic characteristics | ||||||
Age, years, median (IQR), years | 63.0 (55.0, 70.0) | 62.0 (53.0, 70.0) | 63.0 (55.0, 71.0) | 63.0 (55.0, 70.0) | 63.0 (55.0, 70.0) | < 0.0001 |
Male, n (%) | 6689 (68.9) | 1701 (70.1) | 1680 (69.2) | 1664 (68.5) | 1644 (67.7) | 0.34 |
BMI (kg/m2), median (IQR) | 24.5 (22.6, 26.6) | 24.6 (22.9, 26.7) | 24.5 (22.6, 26.6) | 24.4 (22.6, 26.6) | 24.2 (22.5, 26.3) | 0.001 |
Current smoker, n (%) | 3102 (31.9) | 780 (32.1) | 766 (31.6) | 790 (32.5) | 766 (31.6) | 0.86 |
Medical history, n (%) | ||||||
Hypertension | 6112 (63.0) | 1536 (63.3) | 1517 (62.5) | 1535 (63.2) | 1524 (62.8) | 0.94 |
Diabetes mellitus | 2340 (24.1) | 621 (25.6) | 587 (24.2) | 561 (23.1) | 571 (23.5) | 0.2 |
Hyperlipidemia | 778 (8.0) | 182 (7.5) | 190 (7.8) | 192 (7.9) | 214 (8.8) | 0.37 |
TIA, n (%) | 221 (2.3) | 57 (2.3) | 57 (2.3) | 57 (2.3) | 50 (2.1) | 0.88 |
TOAST subtype, n (%) | < 0.0001 | |||||
LAA | 2488 (25.6) | 569 (23.4) | 591 (24.4) | 619 (25.5) | 709 (29.2) | |
CE | 639 (6.6) | 175 (7.2) | 173 (7.1) | 150 (6.2) | 141 (5.8) | |
SAO | 2162 (22.3) | 536 (22.1) | 562 (23.2) | 584 (24.0) | 480 (19.8) | |
Others | 4420 (45.5) | 1148 (47.3) | 1100 (45.3) | 1075 (44.3) | 1097 (45.2) | |
TPA, n (%) | ||||||
Yes | 908 (9.3) | 219 (9.0) | 234 (9.6) | 221 (9.1) | 234 (9.6) | 0.8 |
No | 8801 (90.6) | 2209 (91.0) | 2192 (90.3) | 2207 (90.9) | 2193 (90.4) | |
Laboratory test | ||||||
SBP at admission (mmHg), median (IQR) | 149.0(135.0, 165.0) | 148.5(135.0, 163.5) | 149.5(136.5, 165.0) | 149.5(135.0, 165.0) | 149.0(135.0, 165.0) | 0.32 |
FPG (mM), median (IQR) | 5.6 (4.9, 7.0) | 5.7 (5.0, 7.2) | 5.6 (4.9, 7.1) | 5.5 (4.9, 6.9) | 5.5 (4.9, 6.8) | 0.02 |
Baseline LDL-C (mM), median (IQR) | 2.3 (1.8, 3.0) | 2.1 (1.5, 2.7) | 2.3 (1.7, 2.9) | 2.4 (1.9, 3.1) | 2.6 (2.0, 3.3) | < 0.0001 |
Baseline HDL-C (mM), median (IQR) | 1.1 (0.9, 1.3) | 1.0 (0.9, 1.3) | 1.1 (0.9, 1.3) | 1.1 (0.9, 1.3) | 1.1 (0.9, 1.3) | < 0.0001 |
Baseline TG (mM), median (IQR) | 1.4 (1.0, 1.9) | 1.5 (1.1, 2.1) | 1.4 (1.1, 1.9) | 1.4 (1.0, 1.8) | 1.3 (1.0, 1.7) | < 0.0001 |
Baseline hsCRP (mg/L), median (IQR) | 1.8 (0.8, 4.8) | 1.6 (0.8, 3.7) | 1.8 (0.8, 4.7) | 2.0 (0.9, 5.0) | 2.0 (0.9, 5.9) | < 0.0001 |
Baseline Lp-PLA2 (ng/mL), median (IQR) | 175.6 (127.3, 226.4) | 168.2 (119.4, 217.0) | 169.5 (123.0, 218.2) | 177.7 (132.3, 228.8) | 186.6 (137.1, 238.2) | < 0.0001 |
Discharge medication, n (%) | ||||||
Lipid-lowering drugs | 9040 (93.4) | 2254 (93.0) | 2262 (93.6) | 2249 (92.9) | 2275 (94.0) | 0.34 |
Antiplatelet agents | 8925 (92.2) | 2248 (92.7) | 2211 (91.5) | 2237 (92.4) | 2229 (92.1) | 0.4 |